Complement C1 inhibitor protein: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett (New page: In medicine, '''complement C1 inhibitor protein''' ('''C1 esterase inhibitor''' or '''C1 INH protein''') is an "endogenous serine protease inhibitor (serpins). It is a 105-kDa plasma g...) |
mNo edit summary |
||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
In [[medicine]], '''complement C1 inhibitor protein''' ('''C1 esterase inhibitor''' or '''C1 INH protein''') is an "endogenous serine protease inhibitor (serpins). It is a 105-kDa plasma glycoprotein, encoded by C1NH gene and produced primarily by the liver and monocytes. It inhibits a broad spectrum of proteases, including the complement c1r and the complement C1S proteases of the classical complement pathway, and the mannose-binding protein-associated serine proteases. C1-INH-deficient individuals suffer from [[hereditary angioedema]]".<ref>{{MeSH}}</ref> | {{subpages}} | ||
In [[medicine]] and [[immunology]], '''complement C1 inhibitor protein''' ('''C1 esterase inhibitor''' or '''C1 INH protein''') is an "endogenous serine protease inhibitor (serpins). It is a 105-kDa plasma glycoprotein, encoded by C1NH gene and produced primarily by the liver and monocytes. It inhibits a broad spectrum of proteases, including the complement c1r and the complement C1S proteases of the classical complement pathway, and the mannose-binding protein-associated serine proteases. C1-INH-deficient individuals suffer from [[hereditary angioedema]]".<ref>{{MeSH}}</ref> | |||
[[Angioedema]] due to deficiency of complement C1 inhibitor protein may also be acquired.<ref name="pmid10644276">{{cite journal |author=Markovic SN, Inwards DJ, Frigas EA, Phyliky RP |title=Acquired C1 esterase inhibitor deficiency |journal=Ann. Intern. Med. |volume=132 |issue=2 |pages=144–50 |year=2000 |month=January |pmid=10644276 |doi= |url=http://www.annals.org/cgi/pmidlookup?view=long&pmid=10644276 |issn=}}</ref><ref name="pmid12861105">{{cite journal |author=Cicardi M, Zingale LC, Pappalardo E, Folcioni A, Agostoni A |title=Autoantibodies and lymphoproliferative diseases in acquired C1-inhibitor deficiencies |journal=Medicine (Baltimore) |volume=82 |issue=4 |pages=274–81 |year=2003 |month=July |pmid=12861105 |doi=10.1097/01.md.0000085055.63483.09 |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0025-7974&volume=82&issue=4&spage=274 |issn=}}</ref> | |||
==References== | ==References== | ||
<references/> | <references/>[[Category:Suggestion Bot Tag]] | ||
Latest revision as of 11:01, 31 July 2024
In medicine and immunology, complement C1 inhibitor protein (C1 esterase inhibitor or C1 INH protein) is an "endogenous serine protease inhibitor (serpins). It is a 105-kDa plasma glycoprotein, encoded by C1NH gene and produced primarily by the liver and monocytes. It inhibits a broad spectrum of proteases, including the complement c1r and the complement C1S proteases of the classical complement pathway, and the mannose-binding protein-associated serine proteases. C1-INH-deficient individuals suffer from hereditary angioedema".[1]
Angioedema due to deficiency of complement C1 inhibitor protein may also be acquired.[2][3]
References
- ↑ Anonymous (2024), Complement C1 inhibitor protein (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Markovic SN, Inwards DJ, Frigas EA, Phyliky RP (January 2000). "Acquired C1 esterase inhibitor deficiency". Ann. Intern. Med. 132 (2): 144–50. PMID 10644276. [e]
- ↑ Cicardi M, Zingale LC, Pappalardo E, Folcioni A, Agostoni A (July 2003). "Autoantibodies and lymphoproliferative diseases in acquired C1-inhibitor deficiencies". Medicine (Baltimore) 82 (4): 274–81. DOI:10.1097/01.md.0000085055.63483.09. PMID 12861105. Research Blogging.